We assessed the autocrine motility factor receptor (AMFR/gp78) expression i
n thymoma. AMFR/gp78 antigen was identified in tumor cells in 16 out of 51
(31.4%) thymomas. The AMFR/gp78 expression was closely associated with the
stage (I/II vs. III/IV, p<0.0001), pathological subtypes (epithelial vs. ot
her types, p=0.0214), and enhanced expression of ex-smooth-muscle actin wit
hin stroma (p<0.0001). The outcome of the patients with AMFR/gp78 expressio
n was significantly worse than for those without it (p<0.01). All initial t
umors with recurrence expressed AMFR/gp78. The AMFR/gp78 appears to be invo
lved in tumor progression in thymoma.